Research Article
Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis

Hui Liu, Liqiong Lv, Hui Gao, and Ming Cheng

Department of Breast Surgery, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi Province, China

Correspondence should be addressed to Liqiong Lv; llliliqiong@163.com

Received 4 November 2021; Accepted 7 December 2021; Published 31 December 2021

Academic Editor: Tao Huang

Copyright © 2021 Hui Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Earlier research has illustrated prognostic significance of pathologic complete response (pCR) in neoadjuvant therapy (NAT) for breast cancer, whereas correlation between treatment after achieving pCR and survival improvement remains underexplored. We attempted to measure the relation between pCR achieved after NAT and breast cancer recurrence or patient’s survival.

Methods. We searched PubMed, EMBASE, Web of Science, and The Cochrane Library databases to find relevant articles from their inception to November 2020. According to eligibility criteria, studies were selected and basic data were extracted. The primary endpoint was the correlation between pCR achieved after NAT and event-free survival (EFS) or overall survival (OS). The results were obtained by directly extracting specific information from the literature or estimating individual data by survival curves on DigitizeIt software, presented with HR and 95% CI. All data were processed on Stata 14.0 software.

Results. Among 4338 articles, there were 25 eligible articles involving 8767 patients. The EFS of patients achieved pCR after NAT improved obviously (HR = 0.27; 95% CI, 0.24-0.31), especially in triple negative (HR = 0.17; 95% CI, 0.12-0.24) and HER2 positive (HR = 0.24; 95% CI, 0.20-0.30) breast cancer patients. As such, pCR after NAT was implicated in significantly increased OS (HR = 0.32; 95% CI, 0.27-0.37). Conclusion. Achieving pCR after NAT was notably related to the improvement of EFS and OS, especially for patients with triple-negative and HER2-positive breast cancer. pCR can be a surrogate indicator for outcome of breast cancer patients after NAT, as well as a predictor of treatment efficacy after NAT. Besides, well-designed studies are still warranted for confirmation.

1. Introduction

Breast cancer is the most prevalent malignancy among women globally [1], and in China, morbidity and mortality are increasing [2]. About 10%-20% patients present with locally advanced breast cancer (LABC) at diagnosis. At present, neoadjuvant therapy (NAT) is the standard nursing plan for patients in the early stage or those with LABC [3]. Generally, early-stage or operable breast cancer is regarded to be curable in higher probability [4]. Primary objective of NAT is to treat distant metastases as early as possible and shrinkage the size of inoperable tumors, thus, realizing conservative breast surgery [5]. Besides, NAT can help to convert unresectable tumors into resectable tumors, and it can be used to test the sensitivity of tumors to new therapies as well [6]. Compared with postoperative or adjuvant chemotherapy, NAT can achieve a similar overall survival (OS) rate and higher breast preservation rate [7]. Nevertheless, questions have been raised about the correlation between further treatment and patient’s survival after patients achieved pathologic complete response (pCR) by NAT.

Definition of pCR is the absence of invasive disease at surgical resection, which is an essential prognosticator for improving the disease-free survival (DFS) rate and OS rate of HER2-positive and triple-negative breast cancer (TNBC) [8]. Considerable clinical trials support the view that pCR after NAT is implicated in long-term survival benefits [9]. pCR is usually applied as the endpoint for evaluating novel...
therapies in NAT since it be used to predict long-term clinical benefits [10]. But its definition in diverse clinical trials is quite different. Accumulating researches displayed that patients achieved pCR after NAT have markedly better DFS and OS in comparison to patients failed to achieve pCR [11], which assuredly exerts positive effects on drug efficacy evaluation and application.

This study attempted to carry out a comprehensive meta-analysis by obtaining individual data in each article to investigate the correlation between pCR and event-free survival (EFS)/OS of breast cancer patients, thus, providing a reference for predicting long-term efficacy in patients.

2. Materials and Methods

2.1. Literature Retrieval. This investigation was done in compliance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [12]. We searched PubMed, EMBASE, Web of Science, and The Cochrane Library databases to find relevant articles from their inception to November 2020. Then, the reference lists of eligible studies were reviewed, and other publications were identified by citing manuscripts of selected studies. Results in the latest publication were included when multiple publications were reported in the same clinical trial or patient cohort. Search keywords included “breast cancer,” “neoadjuvant treatment,” “pathological complete response,” “pCR,” and “survival outcomes.” The specific search strategy was as follows: (“Breast Neoplasms”[MeSH Terms]) OR (“Breast Neoplasm”[Title/Abstract]) OR (“Breast Tumors”[Title/Abstract]) OR (“Breast Tumor”[Title/Abstract]) OR (“Breast Cancer”[Title/Abstract]) OR (“Breast Carcinoma”[Title/Abstract]) OR (“Breast Carcinomas”[Title/Abstract]) AND (“Neoadjuvant Therapy”[MeSH Terms]) OR (“Neoadjuvant Therapies”[Title/Abstract]) OR (“Neoadjuvant Treatment” [Title/Abstract]) OR (“Neoadjuvant Treatments”[Title/Abstract]) AND (“pathological complete response”[Title/Abstract]) OR (“pCR”[Title/Abstract]).

2.2. Literature Selection. Inclusion criteria were as follows: (1) pathologically diagnosed as breast cancer patients and did not receive surgical resection or failed chemotherapy; (2) the study reported the pCR results after NAT and recurrence and/or survival rate of breast cancer with or without pCR, and the sample size was not less than 25 patients; (3) individual data can be obtained from Kaplan-Meier (KM) curves; (4) clinical trials, prospective cohort studies or retrospective cohort studies. Exclusion criteria were as below: (1) conference abstracts, comments, case reports, letters, editorials, or news; (2) research on patients with unresectable or
Table 1: Baseline characteristics of the included literature.

| Author      | Year | Phase | Study type | Median age (range) | Treatment                                                                 | Subtypes included          | Definition | Measure of recurrence | Sample size | pCR (%) | With pCR | Without pCR | With pCR | Without pCR | With pCR | Without pCR |
|-------------|------|-------|------------|-------------------|-----------------------------------------------------------------------------|---------------------------|------------|-----------------------|-------------|---------|----------|-------------|----------|-------------|----------|-------------|
| Zelnak      | 2015 | II    | Retrospective | 49 (36-64)    | Nab-paclitaxel followed by vinorelbine and trastuzumab                     | HER2                      | ypT0/is ypN0 | DFS                  | 27          | 13/27   | 2/13     | 3/14        |          |             |          |             |
| Mayer       | 2015 | II    | Retrospective | 46 (26-64)    | Paclitaxel/trastuzumab (TH) or vinorelbine/trastuzumab (NH)                | HER2                      | ypT0/is ypN0 | RFS                  | 80          | 14/80   | 3/14     | 21/66       |          |             |          |             |
| Gonzalez    | 2015 | Retrospective |             |                  | Trastuzumab-based NST                                                     | HER2                      | ypT0/is ypN0 | RFS                  | 589         | 203/589 | 7/203    | 54/386      | 5/203    | 33/386      |          |             |
| Cynthia     | 2015 | Retrospective |             | 49 (26-72)     | Neoadjuvant trastuzumab-based chemotherapy                               | HER2                      | ypT0/is ypN0 | DFS                  | 244         | 119/244 | 21/119   | 40/125      | 7/119    | 23/125      |          |             |
| Bear        | 2015 | III   | Prospective  |                  | Docetaxel with capecitabine/gemcitabine/doxorubicin and cyclophosphamide | HER2                      | ypT0/is ypN0 | DFS                  | 1180        | 368/1180 | 52/368   | 243/812     | 29/369   | 167/812     |          |             |
| Ko          | 2015 | Retrospective |             | 43.8 (23-72)  | NAC                                                                         | All                       | ypT0/is ypN0 | RFS                  | 174         | 37/174  | 3/37     | 38/137      |          |             |          |             |
| Liu         | 2015 | Retrospective |             | 53 (23-70)     | Trastuzumab-based NAT                                                      | HER2                      | ypT0/is ypN0 | EFS                  | 108         | 41/108  | 4/41     | 24/67       |          |             |          |             |
| Taher       | 2015 | II    | Prospective  | 43 (25-60)     | Neoadjuvant chemotherapy using epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin and docetaxel, plus trastuzumab if HER2 positive. | HER2                      | ypT0/is ypN0 | DFS                  | 80          | 26/80   | 1/26     | 23/54       | 1/26     | 5/54        |          |             |
| Groheux     | 2016 | Retrospective |             | 51 (27-78)     | EC-D/SIM                                                                   | TNBC                      | ypT0/is ypN0 | EFS                  | 78          | 29/78   | 1/29     | 24/49       |          |             |          |             |
| Shani       | 2016 | Prospective |             |                  | Anthracycline- and taxane-based neo-adjuvant chemotherapy                 | TNBC                      | ypT0/is ypN0 | RFS                  | 77          | 39/77   | 5/39     | 22/38       |          |             |          |             |
| Cynthia     | 2016 | Retrospective |             | 48.9 (42.2-56.7)| NAC                                                                        | All                       | ypT0/is ypN0 | DFS                  | 1639        | 466/1639| 91/1639 | 366/1173    | 37/1173 | 320/1173    |          |             |
| Li          | 2016 | Retrospective |             |                  | Taxane-based or anthracycline-based neo-adjuvant chemotherapy              | TNBC                      | ypT0/is ypN0 | RFS                  | 186         | 42/186  | 5/42     | 44/144      |          |             |          |             |
| Zhang       | 2016 | II    | Prospective  | 47 (24-73)     | Carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neo-adjuvant chemotherapy | TNBC                      | ypT0/is ypN0 | RFS                  | 87          | 23/87   | 1/23     | 28/64       | 1/23     | 21/64       |          |             |
Table 1: Continued.

| Author   | Year | Phase    | Study type | Median age (range) | Treatment | Subtypes included | Definition of pCR | Measure of recurrence | Sample size | pCR (%) | EFS With pCR | Without pCR | OS With pCR | Without pCR |
|----------|------|----------|------------|-------------------|-----------|-------------------|-------------------|---------------------|-------------|---------|-------------|-------------|------------|-------------|
| Shao     | 2016 | Retrospective | NACT      | TNBC              | ypT0/is ypN0 | PFS               | 50                | 14/50 (28)          | 2/14        | 25/36   | 2/14        | 25/61       |
| Choi     | 2017 | Retrospective | 44 (22-68)| Anthracycline and taxane-based NAC | All | DDFS | 353 | 198/353 (56.1) | 33/198 | 69/155 | 15/198 | 37/155 |
| Bignon   | 2017 | Prospective | NAC       | All               | ypT0/is ypN0 | 695               | 192/695 (27.6) | 11/192 | 95/503 |
| Bignon   | 2017 | Retrospective | 39 (25-59)| Anthracycline-based neoadjuvant chemotherapy | TNBC | DDFS | 53 | 23/53 (43.4) | 8/23 | 21/30 | 1/23 | 14/30 |
| Biswas   | 2017 | Retrospective | 51 (21-88)| NACT              | All | DFS | 202 | 67/202 (33.2) | 5/67 | 80/135 | 18/67 | 71/135 |
| Viala    | 2018 | Retrospective | 50        | NAC               | All | PFS | 327 | 107/327 (32.7) | 8/107 | 61/220 | 6/107 | 46/220 |
| Sharma   | 2018 | Prospective | 51        | Neoadjuvant carboplatin plus docetaxel | TNBC | RFS | 183 | 100/183 (54.6) | 10/100 | 28/83 | 6/100 | 17/83 |
| Gass     | 2018 | Retrospective | NACT     | Anthracycline/platinum/taxane-based neoadjuvant chemotherapy | TNBC | DFS | 121 | 56/121 (46.3) | 11/56 | 13/65 |
| Resende  | 2019 | Retrospective | NAC       | All               | ypT0/is ypN0 | DFS | 310 | 43/310 (13.9) | 4/43 | 74/267 | 2/43 | 53/267 |
| Laura    | 2020 | II        | Retrospective | HER2  | ypT0/is ypN0 | EFS | 950 | 330/950 (34.7) | 26/330 | 272/620 |
| Esgueva  | 2020 | Prospective | 53.8 (24–95)| NAT              | All | DFS | 646 | 136/646 (21.1) | 13/136 | 201/510 | 7/136 | 219/510 |
| Hong     | 2020 | Retrospective | NAT       | All               | ypT0/is ypN0 | DFS | 328 | 91/328 (27.7) | 9/91 | 93/237 | 15/91 | 37/237 |
metastatic breast cancer; (3) NAT-related research based on endocrine therapy or radiotherapy. Two investigators independently conducted study selection. Any discrepancies were determined by discussion or judged by a third researcher.

2.3. Data Extraction and Quality Assessment. Two investigators selected data from studies independently: name of the main authors, year of publication, sample size, definition of pCR, patients and tumor characteristics, NAT scheme, and number of patients with an outcome event based on pCR status. The primary endpoints were recurrence rate and OS rate of breast cancer. Besides, a subgroup analysis was carried out based on major breast cancer types. OS was utilized to determine survival outcomes. As for recurrence, there were several indicators described in the literature, including EFS, progression-free survival (PFS), recurrence-free survival (RFS)/relapse-free survival (RFS), and DFS. These indicators were considered equivalent in the summary analysis and were unified as EFS in this study. In this study, pCR was defined as ypT0/Tis ypN0, that is, there were no residual invasive tumor cells in the breast and axillary lymph nodes after NAT. Only a tiny minority of studies analyzed other definitions of pCR: (1) ypT0 ypN0 (no residual invasive disease in the breast and lymph nodes); (2) ypT0/Tis ypN0/+(no disease in the breast); (3) ypN0 (lack of invasive cells in the axillary lymph nodes). The data of patient number regarding relationship between pCR and EFS or OS were obtained by directly extracting specific information from the literature or estimating individual data by KM curves in the literature on DigitizeIt software.

Since included studies were mostly retrospective or prospective cohort studies, the Newcastle-Ottawa Scale (NOS) was introduced for quality assessment [13]. The scale included three major parts, namely, selection of study groups, comparability of groups, and ascertainment of exposure/outcome. It was classified into 8 items and scored according to the semiquantitative principle of the star system. Studies with NOS scores ≥ 6 points out of 9 were deemed high quality.

2.4. Statistics. Statistical analysis was conducted on Stata 14.0 software. HR < 1 indicated that survival outcomes of patients with pCR are superior to patients without pCR. Cochran’s Q test and I² statistics were utilized to assess the heterogeneity between studies. P < 0.01 or I² ≥ 50% indicated a notable heterogeneity, and the random effects model was introduced for analysis. Otherwise, the fixed effects model was utilized. I² lower than 25% was considered as low heterogeneity. I² between 25% and 50% was considered

| Authors | Year | Selection | Comparability | Exposure | Score |
|---------|------|-----------|---------------|----------|-------|
| Zelnak  | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Mayer   | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Gonzalez| 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Cynthia | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Bear    | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Ko      | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Liu     | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Taher   | 2015 | ☆☆☆ | ☆ | ☆ | ☆ | 8 |
| Grobeux | 2016 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Shani   | 2016 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Cynthia | 2016 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Li      | 2016 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Zhang   | 2016 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Shao    | 2016 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Choi    | 2017 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Bignon  | 2017 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Bignon  | 2017 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Biswas  | 2017 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Viala   | 2018 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Sharmar | 2018 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Gass    | 2018 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Resende | 2019 | ☆☆☆ | ☆ | ☆ | ☆ | 6 |
| Laura   | 2020 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
| Esgueva | 2020 | ☆☆☆ | ☆ | ☆ | ☆ | 8 |
| Hong    | 2020 | ☆☆☆ | ☆ | ☆ | ☆ | 7 |
Study | HR (95% CI) | pCR/N | No pCR/N
--- | --- | --- | ---
HER2<br>Zelnak (2015)<br>Mayer (2015)<br>Gonzalez (2015)<br>Cynthia (2015)<br>Bear (2015)<br>Liu (2015)<br>Taher (2015)<br>Subtotal (I-squared = 0.0%, \(p = 0.936\))<br><br>All<br>Ko (2015)<br>Cynthia (2016)<br>Choi (2017)<br>Viala (2018)<br>Resende (2019)<br>Esgueva (2020)<br>Hong (2020)<br>Subtotal (I-squared = 76.3%, \(p = 0.000\))<br><br>TNBC<br>Groheux (2016)<br>Shani (2016)<br>Li (2016)<br>Zhang (2016)<br>Shao (2016)<br>Bignon (2017)<br>Biswas (2017)<br>Sharma (2018)<br>Gass (2018)<br>Subtotal (I-squared = 69.6%, \(p = 0.000\))<br><br>Overall (I-squared = 74.3%, \(p = 0.000\))

Figure 2: Forest plot of the summarized results regarding EFS.

Study | HR (95% CI) | pCR/N | No pCR/N
--- | --- | --- | ---
HER2<br>Gonzalez (2015)<br>Cynthia (2015)<br>Bear (2015)<br>Taher (2015)<br>Subtotal (I-squared = 0.0%, \(p = 0.936\))
<br>All<br>Cynthia (2016)<br>Choi (2017)<br>Bignon (2017)<br>Viala (2018)<br>Resende (2019)<br>Hong (2020)<br>Subtotal (I-squared = 77.8%, \(p = 0.000\))
<br>TNBC<br>Zhang (2016)<br>Shao (2016)<br>Bignon (2017)<br>Biswas (2017)<br>Sharma (2018)<br>Subtotal (I-squared = 29.2%, \(p = 0.227\))<br><br>Overall (I-squared = 56.1%, \(p = 0.003\))

Figure 3: Forest plot of the summarized results regarding OS.
as medium heterogeneity. I² higher than 75% was considered as high heterogeneity. When there was a large heterogeneity, subgroup analysis of major biological subtypes of breast cancer and sensitivity analysis was carried out to investigate potential sources of heterogeneity. The publication bias was measured by observing the funnel plot and performing Egger’s test. \( P < 0.05 \) means statistical significance.

3. Results

3.1. Literature Selection Results. We identified 4338 records by preliminary search, and 1086 duplicate studies were excluded, 2579 studies were removed by browsing titles and abstracts, and then, 673 studies were reviewed in full text. Among them, 639 studies that failed to meet the eligibility criteria and 9 studies that failed to meet the pCR definition or literature type were deleted. 25 studies were deemed eligible in this investigation (Figure 1).

3.2. Literature Characteristics and Quality Assessment. The 25 included studies involved 8767 patients, and the publication years of articles were from 2015 to 2020. Among them, 18 studies were retrospective cohort studies [14–31], and 7 studies were prospective cohort studies [32–38]. Various types of NAT were utilized in the included studies, including anthracycline-based drugs, taxanes, and platinum plus docetaxel. In this study, the pCR of breast cancer after NAT was between 13.9 and 56.1%. Basic characteristics of literature

### Table 1: Meta-analysis estimates, given named study is omitted

| Study          | Lower CI limit | Estimate | Upper CI limit |
|----------------|---------------|---------|---------------|
| Gonzalez (2015)|               |         |               |
| Mayer (2015)   |               |         |               |
| Gonzalez (2015)|               |         |               |
| Cynthia (2015) |               |         |               |
| Bear (2015)    |               |         |               |
| Ko (2015)      |               |         |               |
| Liu (2015)     |               |         |               |
| Taher (2015)   |               |         |               |
| Grotzhaus (2016)|            |         |               |
| Shani (2016)   |               |         |               |
| Cynthia (2016) |               |         |               |
| Li (2016)      |               |         |               |
| Zhang (2016)   |               |         |               |
| Shao (2016)    |               |         |               |
| Choi (2017)    |               |         |               |
| Bignon (2017)  |               |         |               |
| Biwias (2017)  |               |         |               |
| Viala (2018)   |               |         |               |
| Sharma (2018)  |               |         |               |
| Gass (2018)    |               |         |               |
| Resende (2019) |               |         |               |
| Laura (2020)   |               |         |               |
| Esgueva (2020) |               |         |               |
| Hong (2020)    |               |         |               |

### Figure 4: Sensitivity analysis on EFS.

### Figure 5: Sensitivity analysis on OS.
Funnel plot with pseudo 95% confidence limits

(a)

Figure 6: Continued.
were presented in Table 1. Detailed results of literature quality assessment were depicted in Table 2. All of the included studies were in high-quality.

3.3. Meta-Analysis Results

3.3.1. Summarized Results of EFS and OS of Patients with pCR and without pCR.

As depicted in Figure 2, the EFS of patients who achieved pCR after NAT improved noticeably (HR \( = 0.27 \); 95% CI, 0.24-0.31). 9 studies analyzed TNBC patients, and the summarized pCR results were (HR = 0.17; 95% CI, 0.12-0.24). 8 studies analyzed HER2 + breast cancer patients, and the summarized pCR results were (HR = 0.24; 95% CI, 0.20-0.30). Similar to the EFS results, pCR after NAT was also correlated with increased OS (HR = 0.32; 95% CI, 0.27-0.37) (Figure 3). To sum up, pCR exerts an effect on the improvement of survival outcomes both EFS and OS after NAT.

3.3.2. Sensitivity Analysis.

The summarized results of EFS (Figure 4) and OS (Figure 5) showed high and moderate heterogeneity (EFS: \( I^2 = 74.3\% \), \( P \leq 0.001 \); OS: \( I^2 = 56.1\% \), \( P = 0.003 \)); therefore, we carried out a sensitivity analysis. In the EFS results, two studies influenced results. As such, in the OS results, two studies affected overall results.

3.3.3. Publication Bias.

By plotting and observing the funnel chart (Figure 6), we found that the funnel chart was basically symmetrical and mostly located on the top. Besides, Egger’s test results (EFS, \( P = 0.011 \); OS, \( P = 0.274 \)) displayed that there was publication bias in EFS, but no bias in OS.

4. Discussion

There is an increasing trend of incidence of breast cancer in China. Numerous studies revealed that qCR can be a surrogate for survival endpoint to further evaluate the efficacy. But whether patients who achieve pCR after receiving NAT can have more beneficial survival outcomes after receiving NAT remains underexplored. We summarized the results of multiple clinical trials that analyzed the above issues. The results displayed that patients who achieved pCR after NAT were implicated in low recurrence rate and favorable survival outcomes.

The clinical outcomes of NAT are closely related to therapeutic plans. A retrospective study assessed efficacy and safety of nanoparticle albumin-bound paclitaxel-based chemotherapy (nPBC) and docetaxel-based chemotherapy (DBC) as NAT for breast cancer, revealing that nPBC is correlated with favorable pCR [39]. We analyzed patients with main biological subtypes of breast cancer (HER2-positive breast cancer and TNBC). Recently, a study [31] disclosed that early response of breast cancer patients treated with NAT was remarkably implicated in an increased pCR rate, especially in patients with HER2 overexpression. The most remarkable thing is that some studies pointed out the physical characteristics of breast cancer patients. For instance, a meta-analysis showed that NAT efficacy is more significant in postmenopausal hormone receptor- (HR-) positive breast cancer patients than others [40]. The latest meta-analysis investigated the relationship between pCR and long-term survival in TNBC patients [41]. Our results, consistent with the above meta-analysis that pCR can notably improve patient’s EFS and OS. Another study produced similar findings [42]. Overall, these findings convinced us of the prognostic value of pCR in breast cancer NAT.

Despite gains in this study, some limitations are still existed, which may lead to deviations of the results. First, we have conducted a subgroup analysis of multiple tumor types to assess potential sources of heterogeneity, but we are unable to carry out hierarchical analysis on patients based on baseline information (age, stage at diagnosis, tumor size, grade, or NAT). Only few articles describe these features or are incomplete. Besides, classification and definition of these features are quite different, which makes subgroup analysis challenging. Second, different definitions of EFS in the included studies make us hard to analyze the heterogeneity
of EFS results. Nevertheless, the definitions of pCR and no pCR in each study are still applicable, and thus, the correlation of pCR and survival is credible. Third, the eligibility criteria of patients receiving NAT and the regimens of NAT are quite different, which may affect survival results. Finally, all NATs in this study are chemotherapies, and it is not ruled out that the relationship of pCR and survival seems to vary depending on different treatments. Hence, the relationship of pCR and EFS/OS needs to be reassessed when research data about novel drugs, like immunotherapy, are obtained. For instance, the KEYNOTE-173 study assessed pembrolizumab combined with chemotherapy as a NAT for TNBC and displayed that pCR is positively correlated with tumor PD-L1 expression and sTIL levels [43], which may be a breakthrough for research on novel NAT.

In conclusion, this meta-analysis summarized recent clinical data and proved that pCR achieved after NAT was implicated in the improvement of EFS and OS after subsequent treatment. NAT can provide breast cancer patients with additional clinical benefits regardless of whether they have achieved pCR. But more clinical trials are warranted to provide evidence for the application of clinical adjuvant therapy.

Data Availability
The [DATA TYPE] data used to support the findings of this study are included within the article.

Consent
All authors consent to submit the manuscript for publication.

Conflicts of Interest
The authors declare that they have no potential conflicts of interest.

Authors’ Contributions
HL contributed to the study design. LQ conducted the literature search. HG acquired the data. CM wrote the article. HL performed data analysis. MC drafted the article and gave the final approval of the version to be submitted. All authors read and approved the final manuscript.

Acknowledgments
This study received funding from (1) Research Project of Self Financing by Health and Family Planning Commission of Guangxi Zhuang Autonomous Region, Z2015433; and (2) Research Project of Self Financing by Guangxi Traditional Chinese Medicine and Ethnic Medicine, GZZC15-28.

References
[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[2] R. M. Feng, Y. N. Zong, S. M. Cao, and R. H. Xu, “Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics,” Cancer Communications, vol. 39, no. 1, 2019.

[3] J. S. Vaidya, S. Massarut, H. J. Vaidya et al., “Rethinking neoadjuvant chemotherapy for breast cancer,” BMJ, vol. 360, article j5913, 2018.

[4] Y. Huang, Z. Tong, K. Chen et al., “Interpretation of breast cancer screening guideline for Chinese women,” Cancer Biology & Medicine, vol. 16, no. 4, pp. 825–835, 2019.

[5] A. M. Thompson and S. L. Moulder-Thompson, “Neoadjuvant treatment of breast cancer,” Annals of Oncology, vol. 23, Supplement 10, pp. x231–x236, 2012.

[6] C. Selli and A. H. Sims, “Neoadjuvant therapy for breast cancer as a model for translational research,” Breast Cancer (Auckl.), vol. 13, p. 117823419829072, 2019.

[7] "Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials," The Lancet Oncology, vol. 19, no. 1, pp. 27–39, 2018.

[8] A. Berruti, D. Generali, M. P. Brizzi, M. Ardine, L. Dogliotti, and A. Bottini, "Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzumab?,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 23, 2005.

[9] P. Cortazar, L. Zhang, M. Untch et al., "Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis," Lancet, vol. 384, no. 9938, pp. 164–172, 2014.

[10] P. Cortazar and C. E. Geyer Jr., "Pathological complete response in neoadjuvant treatment of breast cancer," Annals of Surgical Oncology, vol. 22, no. 5, pp. 1441–1446, 2015.

[11] Q. Wang-Lopez, N. Chalabi, C. Abrial et al., "Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?,” Critical Reviews in Oncology/Hematology, vol. 95, no. 1, pp. 88–104, 2015.

[12] L. Shamseer, D. Moher, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation,” BMJ, vol. 349, article g7647, 2015.

[13] A. Stang, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses," European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010.

[14] A. B. Zelnak, P. Nikolinas, J. Srivivasiah et al., “High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy,” Clinical Breast Cancer, vol. 15, no. 1, pp. 31–36, 2015.

[15] E. L. Mayer, A. B. Gropper, L. Harris et al., “Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer,” Clinical Breast Cancer, vol. 15, no. 1, pp. 24–30, 2015.

[16] A. M. Gonzalez-Angulo, N. Parinivasiah et al., “Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy,” British Journal of Cancer, vol. 112, no. 4, pp. 630–635, 2015.

[17] C. Villarreal-Garza, E. Soto-Perez-de-Celis, E. Sifuentes et al., "Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant
chemotherapy and trastuzumab in Mexico,” *Breast*, vol. 24, no. 3, pp. 218–223, 2015.

[18] E. S. Ko, H. Han, B. K. Han et al., “Prognostic significance of a complete response on breast MRI in patients who received neoadjuvant chemotherapy according to the molecular subtype,” *Korean Journal of Radiology*, vol. 16, no. 5, pp. 986–995, 2015.

[19] S. Liu, X. Duan, L. Xu et al., “Nuclear Gli1 expression is associated with pathological complete response and event-free survival in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant therapy,” *Tumour Biology*, vol. 37, no. 4, pp. 4873–4881, 2016.

[20] D. Groheux, L. Biard, S. Giacchetti et al., “18F-FDG PET/CT for the early evaluation of response to neoadjuvant treatment in triple-negative breast cancer: influence of the chemotherapy regimen,” *Journal of Nuclear Medicine*, vol. 57, no. 4, pp. 536–543, 2016.

[21] C. Villarreal-Garza, J. E. Bargallo-Rocha, E. Soto-Perez-de-Celis et al., “Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy,” *Breast Cancer Research and Treatment*, vol. 157, no. 2, pp. 385–394, 2016.

[22] J. Li, S. Chen, C. M. Chen et al., “Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy,” *Oncotarget*, vol. 8, no. 11, pp. 18399–18408, 2017.

[23] Z. Shao, S. Chaudhri, M. Guo, L. Zhang, and D. Rea, “Neoadjuvant chemotherapy in triple negative breast cancer: an observational study,” *Oncology Research*, vol. 23, no. 6, pp. 291–302, 2016.

[24] M. Choi, Y. H. Park, J. S. Ahn et al., “Evaluation of pathologic complete response in breast cancer patients treated with neoadjuvant chemotherapy: experience in a single institution over a 10-year period,” *J Pathol Transl Med*, vol. 51, no. 1, pp. 69–78, 2017.

[25] L. Bignon, J. P. Fricker, C. Nogues et al., “Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers,” *The Breast Journal*, vol. 24, no. 3, pp. 269–277, 2018.

[26] T. Biswas, J. T. Efird, S. Prasad, C. Jindal, and P. R. Walker, “The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer,” *Oncotarget*, vol. 8, no. 68, pp. 112712–112719, 2017.

[27] M. Viala, A. Chiba, S. Thezenas et al., “Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study,” *BMC Cancer*, vol. 18, no. 1, p. 770, 2018.

[28] P. Gass, M. P. Lux, C. Rauh et al., “Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer,” *BMC Cancer*, vol. 18, no. 1, p. 1051, 2018.

[29] U. Resende, C. Cabello, S. O. B. Ramalho, and L. C. Zeferino, “Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response,” *BMC Cancer*, vol. 19, no. 1, p. 601, 2019.

[30] I-SPY2 Trial Consortium, D. Yee, A. M. DeMichele et al., “Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer,” *JAMA Oncology*, vol. 6, no. 9, pp. 1355–1362, 2020.

[31] J. Hong, J. Wu, O. Huang et al., “Early response and pathological complete remission in breast cancer with different molecular subtypes: a retrospective single center analysis,” *Journal of Cancer*, vol. 11, no. 23, pp. 6916–6924, 2020.

[32] H. D. Bear, G. Tang, P. Rastogi et al., “Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG oncology]): secondary outcomes of a phase 3, randomised controlled trial,” *The Lancet Oncology*, vol. 16, no. 9, pp. 1037–1048, 2015.

[33] T. al-Tweigeri, A. AlSayed, S. Alawadi et al., “A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer,” *Cancer Chemotherapy and Pharmacology*, vol. 77, no. 1, pp. 147–153, 2016.

[34] S. Paluch-Shimon, E. Friedman, R. Berger et al., “Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers,” *Breast Cancer Research and Treatment*, vol. 157, no. 1, pp. 157–165, 2016.

[35] P. Zhang, Y. Yin, H. Mo et al., “Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial,” *Oncotarget*, vol. 7, no. 37, pp. 60647–60656, 2016.

[36] J. C. Boughey, K. V. Ballman, L. M. McCall et al., “Tumor biology and response to chemotherapy impact breast cancer-specific survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy: long-term follow-up from ACSOOG Z1071 (Alliance),” *Annals of Surgery*, vol. 266, no. 4, pp. 667–676, 2017.

[37] P. Sharma, S. López-Tarruella, J. A. García-Saenz et al., “Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel,” *Clinical Cancer Research*, vol. 24, no. 23, pp. 5820–5829, 2018.

[38] A. Esgueva, C. Siso, M. Espinosa-Bravo et al., “Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments,” *Journal of Surgical Oncology*, vol. 123, no. 1, pp. 71–79, 2021.

[39] Y. Chen, B. Yao, Y. Lv et al., “Nab-paclitaxel-based regimens with docetaxel-based regimens as neoadjuvant treatment for early breast cancer,” *Investigational New Drugs*, vol. 39, no. 2, pp. 524–529, 2021.

[40] Y. Wang, L. He, Y. Song et al., “The tumour response of post-menopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis,” *BMC Womens Health*, vol. 20, no. 1, p. 17, 2020.

[41] M. Huang, J. O’Shaughnessy, J. Zhao et al., “Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis,” *Cancer Research*, vol. 80, no. 24, pp. 5427–5434, 2020.

[42] L. M. Spring, G. Fell, A. Arfe et al., “Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis,” *Clinical Cancer Research*, vol. 26, no. 12, pp. 2838–2848, 2020.

[43] P. Schmid, R. Salgado, Y. H. Park et al., “Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase Ib open-label, multicohort KEYNOTE-173 study,” *Annals of Oncology*, vol. 31, no. 5, pp. 569–581, 2020.